Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
JAMA Oncology（2022）
摘要
ClinicalTrials.gov Identifier: NCT03428217.
更多查看译文
关键词
cabozantinib,renal cell carcinoma,telaglenastat,placebo,cell carcinoma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要